164 related articles for article (PubMed ID: 17960414)
1. Increased retinal toxicity of intravitreal tissue plasminogen activator in a central retinal vein occlusion model.
Yamamoto T; Kamei M; Kunavisarut P; Suzuki M; Tano Y
Graefes Arch Clin Exp Ophthalmol; 2008 Apr; 246(4):509-14. PubMed ID: 17960414
[TBL] [Abstract][Full Text] [Related]
2. Indocyanine green as useful guide for retinal vein cannulation and injection of tissue plasminogen activator in rabbits.
Suzuki K; Suzuki Y; Mizukoshi S; Metoki T; Nakazawa M
Tohoku J Exp Med; 2008 Apr; 214(4):351-8. PubMed ID: 18441511
[TBL] [Abstract][Full Text] [Related]
3. Treatment of recent onset central retinal vein occlusion with intravitreal tissue plasminogen activator: a pilot study.
Glacet-Bernard A; Kuhn D; Vine AK; Oubraham H; Coscas G; Soubrane G
Br J Ophthalmol; 2000 Jun; 84(6):609-13. PubMed ID: 10837386
[TBL] [Abstract][Full Text] [Related]
4. Retinal toxicity of commercial intravitreal tissue plasminogen activator solution in cat eyes.
Hrach CJ; Johnson MW; Hassan AS; Lei B; Sieving PA; Elner VM
Arch Ophthalmol; 2000 May; 118(5):659-63. PubMed ID: 10815158
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal tissue plasminogen activator for acute central retinal vein occlusion.
Lahey JM; Fong DS; Kearney J
Ophthalmic Surg Lasers; 1999 Jun; 30(6):427-34. PubMed ID: 10392729
[TBL] [Abstract][Full Text] [Related]
6. Short-term results of endovascular surgery with tissue plasminogen activator injection for central retinal vein occlusion.
Ishida M; Abe S; Nakagawa T; Hayashi A
Graefes Arch Clin Exp Ophthalmol; 2017 Nov; 255(11):2135-2140. PubMed ID: 28803326
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal and subretinal injection of tissue plasminogen activator (tPA) in the treatment of experimentally created retinal vein occlusion in rabbits.
Ameri H; Kim JG; Ratanapakorn T; Chader GJ; Humayun MS
Retina; 2008 Feb; 28(2):350-5. PubMed ID: 18301042
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal injection of tissue plasminogen activator for central retinal vein occlusion.
Elman MJ; Raden RZ; Carrigan A
Trans Am Ophthalmol Soc; 2001; 99():219-21; discussion 222-3. PubMed ID: 11797310
[TBL] [Abstract][Full Text] [Related]
9. Retinal Penetration of Intravitreally Injected Tissue Plasminogen Activator: A Rat Model Study.
Tal K; Dotan A; Nisgav Y; Dachbash M; Gal-Or O; Ehrlich R; Gaton DD; Weinberger D; Livnat T
Ophthalmic Res; 2018; 59(4):235-240. PubMed ID: 28728144
[TBL] [Abstract][Full Text] [Related]
10. Impact of intravitreal injection of tissue plasminogen activator on full-field electroretinogram in patients with macular oedema secondary to retinal vein occlusion.
Tagami M; Kusuhara S; Imai H; Honda S; Tsukahara Y; Negi A
Ophthalmologica; 2011; 226(2):81-6. PubMed ID: 21625191
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal tissue plasminogen activator in the management of central retinal vein occlusion.
Ghazi NG; Noureddine B; Haddad RS; Jurdi FA; Bashshur ZF
Retina; 2003 Dec; 23(6):780-4. PubMed ID: 14707827
[TBL] [Abstract][Full Text] [Related]
12. Updated cannulation technique for tissue plasminogen activator injection into peripapillary retinal vein for central retinal vein occlusion.
van Overdam KA; Missotten T; Spielberg LH
Acta Ophthalmol; 2015 Dec; 93(8):739-44. PubMed ID: 26310993
[TBL] [Abstract][Full Text] [Related]
13. Retinal toxicity of intravitreal tenecteplase in the rabbit.
Rowley SA; Vijayasekaran S; Yu PK; McAllister IL; Yu DY
Br J Ophthalmol; 2004 Apr; 88(4):573-8. PubMed ID: 15031179
[TBL] [Abstract][Full Text] [Related]
14. Retinal endovascular lysis in ischemic central retinal vein occlusion: one-year results of a pilot study.
Feltgen N; Junker B; Agostini H; Hansen LL
Ophthalmology; 2007 Apr; 114(4):716-23. PubMed ID: 17141322
[TBL] [Abstract][Full Text] [Related]
15. Retinal vein occlusion and low-dose fibrinolytic therapy (R.O.L.F.): a prospective, randomized, controlled multicenter study of low-dose recombinant tissue plasminogen activator versus hemodilution in retinal vein occlusion.
Hattenbach LO; Friedrich Arndt C; Lerche R; Scharrer I; Baatz H; Margaron F; Richard G; Behrens-Baumann W; Ohrloff C
Retina; 2009; 29(7):932-40. PubMed ID: 19584651
[TBL] [Abstract][Full Text] [Related]
16. Retinal vein cannulation with prolonged infusion of tissue plasminogen activator (t-PA) for the treatment of experimental retinal vein occlusion in dogs.
Tameesh MK; Lakhanpal RR; Fujii GY; Javaheri M; Shelley TH; D'Anna S; Barnes AC; Margalit E; Farah M; De Juan E; Humayun MS
Am J Ophthalmol; 2004 Nov; 138(5):829-39. PubMed ID: 15531319
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal triamcinolone treatment for macular edema associated with central retinal vein occlusion and hemiretinal vein occlusion.
Cekiç O; Chang S; Tseng JJ; Barile GR; Weissman H; Del Priore LV; Schiff WM; Weiss M; Klancnik JM
Retina; 2005; 25(7):846-50. PubMed ID: 16205562
[TBL] [Abstract][Full Text] [Related]
18. Tissue Plasminogen Activator as an Antiangiogenic Agent in Experimental Laser-Induced Choroidal Neovascularization in Mice.
Ozone D; Mizutani T; Nozaki M; Ohbayashi M; Hasegawa N; Kato A; Yasukawa T; Ogura Y
Invest Ophthalmol Vis Sci; 2016 Oct; 57(13):5348-5354. PubMed ID: 27727399
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal Tissue Plasminogen Activator Injection for the Treatment of Proliferative Vitreoretinopathy in a Rabbit Model.
Reitblat O; Barayev E; Gal-Or O; Tsessler M; Dotan A
Ophthalmic Res; 2023; 66(1):48-56. PubMed ID: 35772382
[TBL] [Abstract][Full Text] [Related]
20. [Intravitreal tissue plasminogen activator for treatment of central retinal vein occlusion associated with diabetic retinopathy].
Suzuma K; Murakami T; Watanabe D; Miyamoto K; Kita M; Takagi H; Yoshimura N
Nippon Ganka Gakkai Zasshi; 2009 Apr; 113(4):492-7. PubMed ID: 19455970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
